A researcher fired from the University of Kansas Medical Center (KUMC) in 2014 for plagiarizing the work of a Harvard scientist has been barred from receiving Federal U.S. funding for two years.
The sanctions come three years after the U.S. Office of Research Integrity (ORI) tried to impose a three-year ban on funding for Rakesh Srivastava, who appealed the move. In September of this year, Department of Health and Human Services administrative law judge Keith Sickendick recommended a two-year sanction.
Carlo Croce, a prolific cancer researcher at The Ohio State University in Columbus who was the subject of a front page story in The New York Times last year about allegations of misconduct against him, has had most of a lawsuit he filed against the newspaper thrown out.
As first reported by Courthouse News Service, United States District Judge James Graham tossed all but one of Croce’s claims for defamation against the Times and two of its reporters. That claim — which involved a statement in a letter that reporter James Glanz sent Croce as part of his reporting — survived dismissal, but not on grounds that it inflicted emotional distress, Graham ruled.
Five journals published by a prominent cancer research society have retracted a total of 10 papers — most of them by a former researcher at the MD Anderson Cancer Center in Houston.
Nine of the 10 retractions share that researcher, Bharat Aggarwal, as an author. Aggarwal — who more than five years ago threatened to sue us for reporting on an investigation into his work — is now up to 28 retractions, and has left his post at MD Anderson. The AACR is also appending an editor’s note to eight of his other papers — but it has not explained the reason for what it acknowledges is a lag in moving on these articles.
Sometimes, corrections are so extensive, they can only be called one thing: Mega-corrections.
Recently, the Proceedings of the National Academy of Sciences (PNAS) issued a four-page correction notice to a paper about a compound that appeared to reduce the chances a cancer will recur. The notice describes figure duplication, problems with error bars and figure legends — as well as the loss of statistical significance for some data.
According to the authors’ statement in the notice:
A probe into the work of a researcher who studied natural products for cancer had many stops and starts along the way — including five extensions granted by the U.S. Office of Research Integrity — according to documents obtained by Retraction Watch.
Six months ago, the media was ablaze with the findings of a new paper, showing that nearly six percent of cancer cases are caused, at least in part, by obesity and diabetes. But this week, the journal retracted that paper — and replaced it with a revised version.
The new paper doesn’t change the main findings much — the share of all cancers attributable to diabetes and obesity changed from 5.6% to 5.7%, which wouldn’t change any headlines about the original paper. But soon after the paper was published, a group of researchers noticed the authors’ mistake — which was significant enough to prompt the journal to retract the paper entirely, and swap it with a new one.
The former researcher at the University of Texas MD Anderson Cancer Center swapped her own blood samples for those taken from 98 human subjects. The misconduct affects two grant progress reports and two papers; one paper has already been retracted, and the former “research interviewer” — Maria Cristina Miron Elqutub — has agreed to correct or retract the other.
Adel El-Naggar, a co-author on both of the papers also based at the University of Texas MD Anderson Cancer Center, told Retraction Watch: